Radium-223 and Other Radiopharmaceuticals in Prostate Cancer

[1]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[2]  C. Parker,et al.  Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. , 2013 .

[3]  P. Hoskin,et al.  Targeted radio-nuclide therapy of skeletal metastases. , 2013, Cancer treatment reviews.

[4]  M. Tomblyn.  The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[5]  Ø. Bruland,et al.  Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy , 2008 .

[6]  A. T. Cameron.  Radium and Radioactivity , 2007 .

[7]  C. Parker,et al.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.

[8]  S. Fosså,et al.  First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases , 2005, Clinical Cancer Research.

[9]  P. Ell,et al.  Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. , 2004, Urology.

[10]  R. Mould.  The discovery of radium in 1898 by Maria Sklodowska-Curie (1867-1934) and Pierre Curie (1859-1906) with commentary on their life and times. , 1998, The British journal of radiology.

[11]  R. Lerski,et al.  Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[13]  M. Ritter,et al.  High-LET radiations induce a large proportion of non-rejoining DNA breaks , 1977, Nature.

[14]  W. S. Maxfield,et al.  The Use of Radioactive Phosphorus and Testosterone in Metastatic Bone Lesions from Breast and Prostate , 1958, Southern medical journal.

[15]  J. Storaasli,et al.  The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. , 1950, The American journal of roentgenology and radium therapy.

[16]  J. Macintyre.  RADIUM AND ITS THERAPEUTIC EFFECTS , 1903, British medical journal.